Clinical Trials Logo

Clinical Trial Summary

Reducing medications and associated side effects in older adults: an electronic hospital-based intervention


Clinical Trial Description

Polypharmacy, or the concomitant use of 5 drugs or more, is a serious health concern and affects more than half of Canadians aged 65 years and older. It is the number one identifiable risk factor for adverse drug events (ADEs), which are responsible for 27,000 hospital admissions annually in Canada and up to 20% of return visits to the hospital within 30 days of discharge. Many ADEs are preventable or ameliorable through interventions to reduce inappropriate prescribing. MedSafer, the intervention software, applies an electronic set of criteria, previously designed and piloted on one thousand (1000) hospitalized patients by a group of Quebec and Ontario internists, geriatricians, palliative care doctors and pharmacists, to identify potentially inappropriate medications (PIMs) in the hospitalized elderly and generate instructions for the patient and physician for safe discontinuation. The current study seeks to partially automate the deprescribing process and to demonstrate the efficacy of this type of intervention on adverse drug events at 30-days post hospital discharge. At the time of hospitalization, the patient's medications, co-morbidities, and a measure of frailty will be entered into the MedSafer software which will output an individualized and prioritized deprescription plan for the most responsible physician's consideration. Any subsequent medication changes will be transmitted to relevant community physicians. The study will evaluate the impact of stopping PIMs on the occurrence of ADEs within 30 days of discharge, as compared to usual care. This study will take place on the clinical teaching units (CTUs) at 11 hospitals from seven university hospital centres across Canada. Based on historical data, the investigators estimate a combined 5200 eligible patients per year with nearly 50% taking ten or more medications. Many will have multiple medical co-morbidities such as diabetes, heart disease, and renal insufficiency. A large portion will meet criteria for geriatric syndromes such as frailty and will be at high risk for the development of delirium, falls and functional decline. This population is ideal for a generalizable deprescribing study. All patients aged 65 or older who meet inclusion/exclusion criteria will be enrolled. A trained research assistant will identify eligible patients and medications will be screened using MedSafer. A deprescribing plan will be generated for the CTU team containing the rationale for suggested medication changes and strategies for safe and successful deprescription. The CTU team will then decide, in conjunction with the patient/proxy and relevant consultants, whether to apply the suggested modifications. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03272607
Study type Interventional
Source McGill University Health Centre/Research Institute of the McGill University Health Centre
Contact
Status Completed
Phase N/A
Start date August 22, 2017
Completion date March 30, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03638726 - Subconjunctival Atropine and Intracameral Epinephrine for Pupil Dilation in Phacoemulsification Phase 4
Completed NCT05007041 - Simultaneous RZV and aIIV4 Vaccination Phase 4
Suspended NCT02559960 - Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study
Completed NCT05266300 - Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
Completed NCT03112083 - Safety and Tolerability of Krill Powder Supplement in Slightly Overweight People With Moderately Elevated Blood Pressure N/A
Completed NCT05028361 - Simultaneous mRNA COVID-19 and IIV4 Vaccination Study Phase 4
Completed NCT04284553 - Optimizing Electronic Health Record Prompts With Behavioral Economics to Improve Prescribing for Older Adults N/A
Recruiting NCT06120712 - A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of Advanced Melanoma (MIZAR-002) Phase 1/Phase 2
Completed NCT04181775 - Effectiveness of an ADE-related Hospitalization Risk Prediction Tool for Patients (ADE-RED)
Completed NCT02906657 - Medication Reconciliation Using Electronic Pharmaceutical Record: A Multicenter Study in the Hospitalized Elderly N/A
Completed NCT03640273 - Efficacy and Adverse Effects of Prapchompoothaweep Remedy and Loratadine for Treatment in AR Patients Phase 2
Completed NCT02162147 - How Safe Are Our Pediatric Emergency Departments? N/A
Completed NCT01897870 - The Effect of a Pharmacist Home Visit on Drug-related Problems Post-discharge. N/A
Completed NCT03725046 - Impact of an Optimized Communication on the Readmission for Adverse Drug Event N/A
Recruiting NCT04635956 - Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas Phase 2
Active, not recruiting NCT05538065 - NUDGE-EHR Replication Trial at Mass General Brigham N/A
Completed NCT03442010 - Adverse Drug Events at Emergency Department
Recruiting NCT04791150 - Rheumatologic Adverse Events and Cancer Immunotherapy N/A
Completed NCT02864030 - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Phase 4
Completed NCT03665402 - A Pharamcogenomic Study for Isoniazid According to NAT2 Polymorphism Status N/A